Dr. Bhatt is a pulmonary/critical care and sleep medicine physician at the Ohio State University (OSU) with a clinical and academic interest in interstitial lung diseases. He has been Medical Director of the OSU Interstitial Lung Diseases Center and led its participation in the Pulmonary Fibrosis Foundation (PFF) Care Center Network and Patient Registry. He has also been involved with the American Thoracic Society Environmental Health Policy Committee and the American College of Chest Physicians, most recently as Chair of the Occupational and Environmental Health Section of Diffuse Lung Disease and Lung Transplant Network.

His background includes basic science research in monocyte and macrophage biology as related to interstitial lung diseases, and he has been involved in therapeutic clinical trials, including studies in interstitial lung disease and idiopathic pulmonary fibrosis, and associated conditions including autoimmune disease and pulmonary hypertension. He also has a clinical interest in pulmonary physiology and pulmonary function testing and has been Medical Director of Ohio State's Pulmonary Diagnostics and Bronchoscopy Labs.

He is ABIM Board Certified in Pulmonary Disease, Critical Care Medicine and Sleep Medicine and actively maintains practice in pulmonary, critical care and sleep medicine.

Dr. Bhatt earned a bachelor's degree in electrical engineering from Ohio State University, where he also completed his internal medicine training and pulmonary/critical care fellowship training. 

As of September 2024, Dr. Bhatt reported no ongoing external relationships.

Dr. Chang is a pulmonary and critical care physician at Scripps Clinic in La Jolla, California. She is ABIM Board Certified in Pulmonary Disease and has served as Division Head of Pulmonary, Critical Care and Sleep Medicine at Scripps Clinic since 2006. She also serves as Medical Director of the pulmonary function laboratories and the thoracic oncology service.

Through the Scripps MD Anderson Cancer Center affiliation, Dr. Chang holds an affiliate appointment with the University of Texas MD Anderson Cancer Center. She has held several leadership roles within Scripps Clinic Medical Group, including membership on the Medical Executive Committee and various leadership selection committees.

Her current responsibilities focus primarily on clinical care, with particular expertise in fibrosing parenchymal lung disease. She remains actively engaged in administrative leadership, resident teaching and clinical research.

Dr. Chang received her undergraduate degree in biology and economics with honors in both through Stanford University. She also received her medical degree and completed her internal medicine residency training at Stanford. She went on to complete her fellowship training in pulmonary and critical care medicine at the University of Washington, where she also earned a Master of Science in Epidemiology from the University of Washington School of Public Health.

As of April 2025, Dr. Chang reported no ongoing external relationships.

Dr. Fagan is Chief of the Division of Pulmonary and Critical Care Medicine at the University of South Alabama (USA) in Mobile, where she is also Professor of Medicine and Pharmacology. She is a member of the Center for Lung Biology and Director of the Pulmonary Hypertension Center at USA Health. Prior to this role, Dr. Fagan was a faculty member in the Division of Pulmonary Sciences and Critical Care Medicine at the University of Colorado, eventually rising to Associate Professor. At Colorado, she developed a clinical and scientific interest in pulmonary hypertension and received a National Institutes of Health K08 award followed by R01s and other extramural and intramural funding. In addition, she has served on numerous committees and leadership positions in the Pulmonary Hypertension Association and the American Thoracic Society. She is ABIM Board Certified in Internal Medicine, Pulmonary Disease and Critical Care Medicine.

Dr. Fagan graduated with her bachelor’s and medical degrees from the University of California, San Diego and completed internship and residency in internal medicine at the University of Texas Southwestern Medical School in Dallas. After residency, she completed fellowship training in pulmonary and critical care medicine at the University of Colorado in Denver.

As of September 2024, Dr. Fagan reported the following ongoing external relationships:

Dr. Fagan reported that she serves as a grant reviewer for the National Institutes of Health. 

Dr. Krishnan is Professor of Medicine, Professor of Public Health and Associate Vice Chancellor for Population Health Sciences at the University of Illinois (UI) Chicago. He is responsible for developing, testing and implementing healthcare interventions to improve care, outcomes and affordability of care for populations served by the UI Health System.

Dr. Krishnan is a leader in the field of healthcare delivery science, including the development of clinical guidelines, clinical effectiveness (“real world”) research, implementation science and integration of human-centered design in health care. He is a member of research consortia funded by the National Institutes of Health (NIH), the Patient Centered Outcomes Research Institute and the American Lung Association for studies in asthma, chronic obstructive pulmonary disease (COPD) and COVID-19. He is ABIM Board Certified in Pulmonary Disease.

He participates in several national and international advisory groups or committees. Examples include the National Heart, Lung, and Blood Institute (NHLBI) NIH CONNECTS Steering Committee, the European Respiratory Society/American Thoracic Society COPD Exacerbations Guidelines (past chair), the Food and Drug Administration Pulmonary and Allergy Drugs Advisory Committee (past chair), the NIH/NHLBI Clinical Trials Review Committee (past chair), the NIH/National Center for Advancing Translational Sciences Special Emphasis Panel for Clinical and Translational Sciences Awards (ad hoc member), the NIH/NHLBI EPR-4 Working Group (member) and the Global Initiative for Asthma. He is an Associate Editor for The American Journal of Respiratory and Critical Care Medicine.

Dr. Krishnan received his medical degree with honors from Baylor College of Medicine in Houston and completed a residency in internal medicine and a fellowship in pulmonary/critical care medicine at the Johns Hopkins Hospital in Baltimore. He received his doctoral degree in clinical investigation from the Johns Hopkins Bloomberg School of Public Health.

As of March 2024, Dr. Krishnan reported the following external relationships:

Service on a research-related expert panel or advisory board for the following companies, with honoraria:

• AstraZeneca, for asthma medications.
• BData, for severe asthma registry.
• CereVu, for a device regarding dyspnea.
• Teva, for expert review.

Dr. Krishnan serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

• The COPD Foundation, Medical Scientific Advisory Board, without compensation.
• The Global Initiative for Asthma, receiving reimbursement for travel expenses.
• The Respiratory Health Association, Board of Directors, without compensation.

Dr. Nana-Sinkam is Chair of the Division of Pulmonary Disease and Critical Care Medicine at Virginia Commonwealth University (VCU). He holds the Linda Grandis Blatt Chair in Lung Cancer Research. A member of both the Cancer Cell Signaling and Cancer Prevention and Control research programs at the Massey Cancer Center, Dr. Nana-Sinkam’s research has focused on the molecular pathogenesis of lung cancer and identification of novel tumor biomarkers for early lung cancer detection and surveillance. He has been well funded by the National Cancer Institute and the National Institute for Drug Abuse.

Dr. Nana-Sinkam is a member of the National Cancer Institute Early Detection Research Network, and helped author the ACCP Lung Cancer Guidelines III (Molecular Biology of Lung Cancer). Dr. Nana-Sinkam has served as a member on a number of National Institutes of Health study sections and is an editorial board member for several scientific journals, including The American Journal of Respiratory and Critical Care Medicine, The Journal of Thoracic Oncology, Frontiers in Thoracic Oncology and Lung Cancer Frontiers.

Dr. Nana-Sinkam previously served as the lead for mentorship in the center for faculty advancement, mentorship and engagement (FAME) at the Ohio State University. He currently serves as the co-principal investigator of the KL2 award in the Wright Center for Clinical and Translational Research at VCU. He has published over 80 original scientific reports, six invited editorials/reviews and 11 book chapters.

Dr. Nana-Sinkam graduated from Wake Forest University School of Medicine. He completed internal medicine internship and residency training at the University of Michigan Health System followed by a fellowship in pulmonary/critical care medicine at the University of Colorado Health Sciences Center. He is ABIM Board Certified in Pulmonary Disease and Critical Care Medicine.

As of May 2025, Dr. Nana-Sinkam reported the following ongoing external relationships:

Dr. Nana-Sinkam serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

• The American Thoracic Society, Associate Editor of The American Journal of Respiratory and Critical Care Medicine, receiving honoraria.
• The National Cancer Institute, Member of Frederick National Laboratories Advisory Committee

Dr. Dixon is the Director of Pulmonary and Critical Care Medicine at the University of Vermont Larner College of Medicine. She is ABIM Board Certified in Pulmonary Disease and Critical Care Medicine.

Since 2001, Dr. Dixon has been an attending physician in the pulmonary and critical care division at the University of Vermont Medical Center. She has served on numerous committees for this organization, including serving as a member of the Board of Trustees of the University of Vermont Medical Group. In addition, she also leads an active research program in obesity and lung disease at the University of Vermont.

She has served on numerous national committees and review boards for the American Thoracic Society, the American Lung Association-Airways Clinical Research Centers, the National Institutes of Health and the Veteran’s Administration.

She received a degree in natural sciences from the University of Cambridge and her medical degree from Oxford University. Dr. Dixon completed residency training at the Johns Hopkins Hospital in Baltimore and fellowship training at the University of Washington in Seattle.

As of August 2024, Dr. Dixon reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Vermont Larner College of Medicine, from the following companies:

• AstraZeneca
• Inverago
• MitoQ 

Dr. Dixon serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

• The American Lung Association, Board Member, without compensation.

Work as an author or editor for the following companies, with compensation as listed:

• UpToDate, receiving compensation for authorship. 

Dr. Allada is an Associate Professor of Medicine in the Division of Pulmonary and Critical Care Medicine for Oregon Health & Science University (OHSU). He also serves as the general Pulmonary Clinic Director and Pulmonary Clinic Quality Improvement Director, as well as the OHSU Adult Cystic Fibrosis Director and Medical Director of the OHSU Physician Assistant school. He is ABIM Board Certified in Pulmonary Disease and Critical Care Medicine.

Dr. Allada participates in clinical research trials for promising cystic fibrosis therapies. He serves on the national Cystic Fibrosis Foundation (CFF) Center Committee and the national CFF Education Committee, and is a board member of the Oregon Chapter of the Cystic Fibrosis Foundation. He is a member of the American Thoracic Society.

He received a medical degree from the University of Michigan Medical School and completed an internship and residency in internal medicine at the University of Wisconsin, Madison. He went on to complete pulmonary and critical care fellowship training at OHSU.

As of April 2025, Dr. Allada reported the following external relationships: 

Dr. Allada serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

• National Board for Respiratory Care, Board of Trustees, without compensation. 

Dr. Bakhru is an Associate Professor of Medicine in the Division of Pulmonary, Critical Care, Allergy and Sleep Medicine at the Medical University of South Carolina (MUSC). She is ABIM Board Certified in Pulmonary Disease and Critical Care Medicine. She previously served on the faculty at Wake Forest University School of Medicine.

Dr. Bakhru spends her clinical time in the ICU and running an ICU Recovery Clinic. She is the Associate Program Director for the Critical Care Fellowship at MUSC and Director of the Specialty Medical ICU.

Dr. Bakhru completed her training in internal medicine at the University of Michigan and a fellowship in pulmonary/critical care medicine at the University of Pennsylvania, as well as a master’s degree in clinical epidemiology.

As of August 2024, Dr. Bakhru reported the following external relationships:

Grant funding from the following nonprofit healthcare-related organization:

• Duke University, endowment for salary support, staff and expenses.

Dr. Gupta is the Director of the University of Cincinnati Interstitial Lung Disease Program and the LAM Foundation Endowed Professor for LAM Research. He is ABIM Board Certified in Internal Medicine, Pulmonary Disease and Critical Care Medicine.

Dr. Gupta completed his medical training at the University of Delhi in India, followed by internal medicine residency at the University of Tennessee and fellowships in pulmonary and critical care medicine at the University of Cincinnati. In addition, he has completed fellowship training in the field of rare lung diseases, as well as a master’s degree in clinical and translational research at the University of Cincinnati.

As of September 2024, Dr. Gupta reported the following external relationships:

Funding for clinical trial expenses, staff and salary support, paid to the University of Cincinnati, from the following companies:

• aTyR, Site Principal Investigator, receiving funding for salary support and project expenses. 
• Boehringer Ingelheim, Site Principal Investigator, receiving funding for salary support and project expenses.
• CSL Behring, Site Principal Investigator, receiving funding for salary support and project expenses.
•  Genentech, Site Principal Investigator, receiving funding for salary support and project expenses. 
• United Therapeutics, Site Principal Investigator, receiving funding for salary support and project expenses. 

Service on data and safety monitoring boards for the following company, with honoraria:

•  LabCorp 
  Work as an author or editor for the following company, with compensation as listed: 
• UpToDate, receiving compensation for authorship. 

Dr. Gupta also reported receiving funding for clinical trial salary support from the National Institutes of Health, paid to the University of Cincinnati, for the following trials:

• Principal Investigator for R21TR003858, Menstrual Cycle-Related Symptom Variability as a Prognostic Indicator in LAM.
• Principal Investigator for NIH/NHLBI 1R21HL172156-01, patient-centered outcome measures and prediction tools in LAM. 

Dr. Patil is the System Director and Section Chief for Sleep Medicine at the University Hospitals of Cleveland and a Clinical Associate Professor of Medicine at Case Western Reserve University. He is ABIM Board Certified in Pulmonary Disease, Critical Care Medicine and Sleep Medicine.

Dr. Patil was previously the Clinical Director of the Johns Hopkins Sleep Medicine Program and the Director of the Johns Hopkins Sleep Medicine Fellowship Program in Baltimore. He has been active in national and regional leadership with roles with the American Thoracic Society, the American College of Chest Physicians and the American Academy of Sleep Medicine. He was previously served on the ABIM Sleep Medicine Test-Writing Committee. He is the former President of the Maryland Sleep Society. He has authored more than 30 publications. Dr. Patil has longstanding research interest in the pathogenesis of obstructive sleep apnea and clinical trials in sleep apnea therapeutics.

He completed his training in pulmonary, critical care and sleep medicine at Johns Hopkins University and his doctoral degree in clinical investigation at the Johns Hopkins Bloomberg School of Public Health.

As of October 2024, Dr. Patil reported the following external relationships:

Work as an author or editor for the following company, with compensation as listed:

• The American College of Chest Physicians, receiving compensation as Associate Editor for CHEST. 

Dr. Patil serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

• The American Academy of Sleep Medicine, Director At-Large, receiving reimbursement for travel expenses and honoraria. 

Dr. Patil also reported consulting for Kramer Levin Naftalis & Frankel LLP as an expert witness. 

Dr. Rivera is a Professor of Medicine in the Division of Pulmonary Diseases and Critical Care Medicine at the University of North Carolina (UNC) at Chapel Hill. She is ABIM Board Certified in Internal Medicine and Pulmonary Disease. She specializes in lung cancer screening, diagnosis, staging and management of treatment complications, and currently serves as Co-Director of the Multidisciplinary Thoracic Oncology Program and Director of the Lung Cancer Screening (LCS) Program at UNC.

She is the Chair of the Thoracic Oncology Network of the American College of Chest Physicians (CHEST) and immediate past chair of the Thoracic Oncology Assembly of the American Thoracic Society (ATS). She has led ATS research workshops on the impact of co-morbidities on LCS, disparities in LCS and immunotherapy-induced lung disease. She serves as Vice Chair of the Lung Cancer in Women Task Force and of the Biomarker Task Force of the National Lung Cancer Round Table (NLCRT), charged to promote awareness of lung cancer as a women's health imperative and barriers to biomarker testing.

Her research interests include lung cancer in women and lung cancer screening. Dr. Rivera is an active participant in the CHEST Lung Cancer Guidelines Initiative and has had an integral part in the guideline's development. She is currently an investigator in National Institutes of Health-funded grants to examine the delivery, quality and outcomes of lung cancer screening in North Carolina, and co-principal investigator of a study to explore rural/urban disparities associated with biomarker testing. Throughout her career, she has worked effectively in multidisciplinary clinical and research settings, using her expertise in lung cancer to promote evidence-based screening, diagnosis, staging and treatment.

As of September 2024, Dr. Rivera reported the following external relationships:

Dr. Rivera serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

• The American Thoracic Society, Chair, Vice President, without compensation. 

Dr. Svetlecic is an attending physician in the St. Luke's Health System where she sees patients in the hospital, in the clinic and virtually via tele-medicine. She was elected by her peers to three terms as Chair of the Department of Medicine at St. Luke's North Hospital and served as its Director of Respiratory Medicine. For the St. Luke's Health System, Dr. Svetlecic was the Director of Medical Staff Development and Chair of the Professional Standards and Credentialing Committee. She is ABIM Board Certified in Pulmonary Disease and Critical Care Medicine.

Dr. Svetlecic has previously served as a member of the ABIM Pulmonary Disease Item-Writing Task Force. She also serves as an outside expert peer reviewer on complex cases through Chartis (formerly The Greeley Company). Dr. Svetlecic formerly held an appointment at the University of Missouri, Kansas City (UMKC) School of Medicine as an Associate Clinical Professor of Medicine and served as a guest faculty member in the Cardiopulmonary Section at the Kansas City University of Medicine and Biosciences.

Dr. Svetlecic received her undergraduate degree in biology and her medical degree from the University of Missouri, Kansas City. She completed a residency in internal medicine and fellowships in pulmonary and critical care medicine at the University of Missouri, Kansas City. 

As of September 2024, Dr. Svetlecic reported no ongoing external relationships.

Dr. Ventetuolo is an Associate Professor of Medicine and Health Services, Policy and Practice at Brown University and Director of Academic Affairs for the Pulmonary, Critical Care and Sleep Division at Brown. She is the Associate Director of the Rhode Island Hospital Pulmonary Hypertension Center and Medical Director of the Adult Extracorporeal Life Support Program.

Her work focuses on sexual dimorphism in pulmonary arterial hypertension (PAH) and right ventricular function, hormonal modulation as a treatment strategy and novel methods of endotyping patients with pulmonary vascular disease. She is also interested in improving quality of care for patients with pulmonary hypertension and those on extracorporeal life support. Dr. Ventetuolo is supported by the American Heart Association and the National Institutes of Health.

Dr. Ventetuolo completed her medical degree at Tufts University School of Medicine in Boston, her residency at Rhode Island Hospital in Providence and her fellowship at NewYork-Presbyterian Hospital.

As of September 2024, Dr. Ventetuolo reported the following external relationships:

Service on a research-related advisory board for the following companies, with honoraria:

• Janssen Biotech
• Merck 

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with honoraria:

• Merck
• Regeneron 

Work as an author or editor for the following company, with compensation as listed:

• EBSCO, receiving compensation as an editor.